Fairmount Funds Management LLC → Apogee Therapeutics, Inc. APGE

Stake: 9.99% Shares: 6,047,027 CUSIP: 03770N101 Class: Common Stock, $0.00001 par value

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

1 transaction

0 buys · 1 sales · 0 awards/exercises

Issuer Cluster

2 13D/G filings on this issuer

1 other filing besides this one

Filer Track Record

7 filings by this filer

6 other filings in the data moat

Short Interest · settle 2026-03-31

DTC 6.07

9,729,380 shares short · +10.6% vs prior

Form 4 Insider Transactions · last 365d

Date	Insider	Role	Type	Shares	Price	Value
2026-04-08	HENDERSON MICHAEL THOMAS	director, officer	Sale	17,800	$82.48	$1.47M

Other 13D/G Filings on Apogee Therapeutics, Inc.

Filed	Form	Filer	Stake	Shares
2024-04-01	SC	Fairmount Funds Management LLC	—	—	view →

Other Filings by Fairmount Funds Management LLC

Filed	Form	Issuer	Stake	Shares
2026-01-22	SCHEDULE	Cogent Biosciences, Inc. COGT	9.90%	16,261,918	view →
2025-03-10	SCHEDULE	Oruka Therapeutics, Inc. ORKA	19.99%	8,511,824	view →
2024-04-01	SC	Dianthus Therapeutics, Inc. /DE/ DNTH	—	—	view →
2024-04-01	SC	Viridian Therapeutics, Inc.\DE VRDN	—	—	view →
2024-04-01	SC	Cogent Biosciences, Inc. COGT	—	—	view →
2024-04-01	SC	Apogee Therapeutics, Inc. APGE	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. $1,500/mo. Pilots welcome.

Request a pilot →